The experience with suramin in advanced prostate cancer

Mario Eisenberger, L. Reyno, Victoria Sinibaldi, R. Sridhara, Michael A Carducci, M. Egorin

Research output: Contribution to journalArticle

Abstract

Suramin is a new experimental polyanionic compound that has shown evidence of antitumor activity in patients with hormone refractory prostate cancer. After a few years of Phase I and Phase II testing, much of the drug's toxicity pattern has been carefully characterized. Similarly, pharmacologic studies have defined many of the drug's complex pharmacologic properties to the extent that simple outpatient methods of drug administration can be easily accomplished. A pharmacologically derived, fixed outpatient schedule has been shown to be safe and effective and is currently in active Phase III development in prostate cancer and will provide more definitive data regarding the role of suramin in the treatment of this disease. Despite these accomplishments, a number of questions require further study, such as definition of pharmacodynamic correlations, effects on the hypothalamic- pituitary-adrenal and gonadal axis, and the nature of its most common dose- limiting toxicity, which is a syndrome of malaise and fatigue.

Original languageEnglish (US)
Pages (from-to)1927-1934
Number of pages8
JournalCancer
Volume75
Issue number7 SUPPL.
StatePublished - 1995

Fingerprint

Suramin
Prostatic Neoplasms
Outpatients
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Fatigue
Appointments and Schedules
Hormones
Therapeutics

Keywords

  • suramin/chemotherapy in prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Eisenberger, M., Reyno, L., Sinibaldi, V., Sridhara, R., Carducci, M. A., & Egorin, M. (1995). The experience with suramin in advanced prostate cancer. Cancer, 75(7 SUPPL.), 1927-1934.

The experience with suramin in advanced prostate cancer. / Eisenberger, Mario; Reyno, L.; Sinibaldi, Victoria; Sridhara, R.; Carducci, Michael A; Egorin, M.

In: Cancer, Vol. 75, No. 7 SUPPL., 1995, p. 1927-1934.

Research output: Contribution to journalArticle

Eisenberger, M, Reyno, L, Sinibaldi, V, Sridhara, R, Carducci, MA & Egorin, M 1995, 'The experience with suramin in advanced prostate cancer', Cancer, vol. 75, no. 7 SUPPL., pp. 1927-1934.
Eisenberger, Mario ; Reyno, L. ; Sinibaldi, Victoria ; Sridhara, R. ; Carducci, Michael A ; Egorin, M. / The experience with suramin in advanced prostate cancer. In: Cancer. 1995 ; Vol. 75, No. 7 SUPPL. pp. 1927-1934.
@article{61703926c4e6478eb17d3994e0cffb5b,
title = "The experience with suramin in advanced prostate cancer",
abstract = "Suramin is a new experimental polyanionic compound that has shown evidence of antitumor activity in patients with hormone refractory prostate cancer. After a few years of Phase I and Phase II testing, much of the drug's toxicity pattern has been carefully characterized. Similarly, pharmacologic studies have defined many of the drug's complex pharmacologic properties to the extent that simple outpatient methods of drug administration can be easily accomplished. A pharmacologically derived, fixed outpatient schedule has been shown to be safe and effective and is currently in active Phase III development in prostate cancer and will provide more definitive data regarding the role of suramin in the treatment of this disease. Despite these accomplishments, a number of questions require further study, such as definition of pharmacodynamic correlations, effects on the hypothalamic- pituitary-adrenal and gonadal axis, and the nature of its most common dose- limiting toxicity, which is a syndrome of malaise and fatigue.",
keywords = "suramin/chemotherapy in prostate cancer",
author = "Mario Eisenberger and L. Reyno and Victoria Sinibaldi and R. Sridhara and Carducci, {Michael A} and M. Egorin",
year = "1995",
language = "English (US)",
volume = "75",
pages = "1927--1934",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7 SUPPL.",

}

TY - JOUR

T1 - The experience with suramin in advanced prostate cancer

AU - Eisenberger, Mario

AU - Reyno, L.

AU - Sinibaldi, Victoria

AU - Sridhara, R.

AU - Carducci, Michael A

AU - Egorin, M.

PY - 1995

Y1 - 1995

N2 - Suramin is a new experimental polyanionic compound that has shown evidence of antitumor activity in patients with hormone refractory prostate cancer. After a few years of Phase I and Phase II testing, much of the drug's toxicity pattern has been carefully characterized. Similarly, pharmacologic studies have defined many of the drug's complex pharmacologic properties to the extent that simple outpatient methods of drug administration can be easily accomplished. A pharmacologically derived, fixed outpatient schedule has been shown to be safe and effective and is currently in active Phase III development in prostate cancer and will provide more definitive data regarding the role of suramin in the treatment of this disease. Despite these accomplishments, a number of questions require further study, such as definition of pharmacodynamic correlations, effects on the hypothalamic- pituitary-adrenal and gonadal axis, and the nature of its most common dose- limiting toxicity, which is a syndrome of malaise and fatigue.

AB - Suramin is a new experimental polyanionic compound that has shown evidence of antitumor activity in patients with hormone refractory prostate cancer. After a few years of Phase I and Phase II testing, much of the drug's toxicity pattern has been carefully characterized. Similarly, pharmacologic studies have defined many of the drug's complex pharmacologic properties to the extent that simple outpatient methods of drug administration can be easily accomplished. A pharmacologically derived, fixed outpatient schedule has been shown to be safe and effective and is currently in active Phase III development in prostate cancer and will provide more definitive data regarding the role of suramin in the treatment of this disease. Despite these accomplishments, a number of questions require further study, such as definition of pharmacodynamic correlations, effects on the hypothalamic- pituitary-adrenal and gonadal axis, and the nature of its most common dose- limiting toxicity, which is a syndrome of malaise and fatigue.

KW - suramin/chemotherapy in prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0028929070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028929070&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028929070

VL - 75

SP - 1927

EP - 1934

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7 SUPPL.

ER -